Corporate Clients

Realise potential, meet goals, and build value.

Results works as a trusted adviser to corporate clients, including some of the world’s leading pharmaceutical companies. Our clients know they can count on our track-record, depth of experience, professionalism and exceptional technical capabilities.

We work closely with corporate clients that need sector specialist advisors for their buy-side or sell-side M&A needs. Our solutions include strategic reviews of business or facility portfolios, support for acquisitions and divestments, as well as advising on licensing transactions for marketed products.

Commitment to client service is a hallmark of our project teams.

Our disciplined approach and strong technical capability allow our corporate clients to execute projects with confidence and achieve their strategic goals.

We pride ourselves on our integrity and straight talking, giving the best advice to our clients. We are focused on getting the best outcome: we think this demands an adviser who will be clear and considered however complex or pressurised the situation.

David Sanders

Managing Director

Services

We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.

M&A

When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.

Divestments

With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business.

Licensing

We support clients with in-licensing, out-licensing, drug licensing, and facility licensing and we understand the complexities that are unique to licensing deals.

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal.

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses.

Recent Deals

Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
Has invested in
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Apr 2022
has received investment from
and EnBW New Ventures, with follow-on investment from ETF Partners
Apr 2022
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF
Apr 2022
has been acquired by
Mar 2022
An AlbionVC-backed company
has received investment from
Morgan Stanley Expansion Capital and Keyhaven Capital Partners co-invest
Mar 2022
has received investment from
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility

Results. Great people creating great outcomes, together.

Latest Insights

Insights
23rd June 2022

BIO International in San Diego: Sunny with scattered economic clouds

The biopharma universe gathered in San Diego last week for the first face to face BIO International conference in three years. Turn-out was good but below the get-together in Philadelphia in 2019. That one topped out above 17,000 attendees according to the BIO website; whisper numbers this time around were in the region of 12,000. I […]

Insights
25th May 2022

Biotech funding in a risk-off climate – does upstream trouble loom for pharma services providers?

Biotech funding is the key driver of innovation in the pharmaceutical industry and is essential in supporting the healthcare ecosystem. More than 80% of drugs marketed by large pharmaceutical companies were discovered and initially developed by biotechs1. Biotech companies also discovered more than 60% of FDA-approved “priority” drugs, which treat life-threatening conditions and offer significant […]

Insights
24th May 2022

Crossrail opens – a big day for travellers to and workers in London

At Results Healthcare we execute transactions around the world, with active projects in North America, Europe and Asia Pacific, so we see ourselves as a global organisation with offices and employees in London and New York, so a blog on transport in London might seem oddly parochial, but the opening of Crossrail, or the Elizabeth […]